Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
BACKGROUND
Radionuclide therapy (RNT) is an effective method for bone pain palliation in patients suffering from bone metastasis. Due to the long half-life, easy production and relatively low beta- energy, (177)Lu [T(1/2)=6.73 days, E(beta max)=497 keV, E(gamma)=113 keV (6.4%), 208 keV (11%)]-based radiopharmaceuticals offer logistical advantage for wider use. This paper reports the results of a multispecies biodistribution and toxicity studies of (177)Lu-EDTMP to collect preclinical data for starting human clinical trials.


METHODS
(177)Lu-EDTMP with radiochemical purity greater than 99% was formulated by using a lyophilized kit of EDTMP (35 mg of EDTMP, 5.72 g of CaO and 14.1 mg of NaOH). Biodistribution studies were conducted in mice and rabbits. Small animal imaging was performed using NanoSPECT/CT (Mediso, Ltd., Hungary) and digital autoradiography. Gamma camera imaging was done in rabbits and dogs. Four levels of activity (9.25 through 37 MBq/kg body weight) of (177)Lu-EDTMP were injected in four groups of three dogs each to study the toxicological effects.


RESULTS
(177)Lu-EDTMP accumulated almost exclusively in the skeletal system (peak ca. 41% of the injected activity in bone with terminal elimination half-life of 2130 and 1870 h in mice and rabbits, respectively) with a peak uptake during 1-3 h. Excretion of the radiopharmaceutical was through the urinary system. Imaging studies showed that all species (mouse, rat, rabbit and dog) take up the compound in regions of remodeling bone, while kidney retention is not visible after 1 day postinjection (pi). In dogs, the highest applied activity (37 MBq/kg body weight) led to a moderate decrease in platelet concentration (mean, 160 g/L) at 1 week pi with no toxicity.


CONCLUSIONS
The protracted effective half-life of (177)Lu-EDTMP in bone supports that modifying the EDTMP molecule by introducing (177)Lu does not alter its biological behaviour as a specific bone-seeking tracer. Species-specific pharmacokinetic behavior differences were observed. Toxicity studies in dogs did not show any biological adverse effects. The studies demonstrate that (177)Lu-EDTMP is a promising radiopharmaceutical that can be further evaluated for establishing as a radiopharmaceutical for human use.
Máthé
Domokos
D
Department of Applied Radioisotopes and Animal Experimentation, National Frédéric Joliot-Curie Institute of Radiobiology and Radiohygiene, H-1221 Budapest, Hungary. mdomokos@hp.osski.hu
Balogh
Lajos
L
Polyák
András
A
Király
Réka
R
Márián
Teréz
T
Pawlak
Dariusz
D
Zaknun
John J
JJ
Pillai
Maroor R A
MR
Jánoki
Gyozo A
GA
D000818:Animals; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000473:pathology* / Q000528:radiation effects; D004285:Dogs; D008297:Male; D051379:Mice; D009942:Organometallic Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity*; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity*; D010146:Pain / Q000532:radiotherapy; D059408:Pain Management; D010166:Palliative Care; D011817:Rabbits; D051381:Rats; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C119503:lutetium ethylenediaminetetramethylene phosphonic acid